RT Journal Article
SR Electronic
T1 A Scalable, Easy-to-Deploy, Protocol for Cas13-Based Detection of SARS-CoV-2 Genetic Material
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.04.20.052159
DO 10.1101/2020.04.20.052159
A1 Jennifer N. Rauch
A1 Eric Valois
A1 Sabrina C. Solley
A1 Friederike Braig
A1 Ryan S. Lach
A1 Naomi J. Baxter
A1 Kenneth S. Kosik
A1 Carolina Arias
A1 Diego Acosta-Alvear
A1 Maxwell Z. Wilson
YR 2020
UL http://biorxiv.org/content/early/2020/04/21/2020.04.20.052159.abstract
AB The COVID-19 pandemic has created massive demand for widespread, distributed tools for detecting SARS-CoV-2 genetic material. The hurdles to scalable testing include reagent and instrument accessibility, availability of highly-trained personnel, and large upfront investment. Here we showcase an orthogonal pipeline we call CREST (Cas13-based, Rugged, Equitable, Scalable Testing) that addresses some of these hurdles. Specifically, CREST pairs commonplace and reliable biochemical methods (PCR) with low-cost instrumentation, without sacrificing detection sensitivity. By taking advantage of simple fluorescence visualizers, CREST allows for a binary interpretation of results. CREST may provide a point-of-care solution to increase the distribution of COVID-19 surveillance.Competing Interest StatementThe authors have declared no competing interest.